Mechanism of action of nonsteroidal anti-inflammatory drugs

American Journal of Medicine

Volumn 104, Issue 3 A, 1998, Pages

  Vane, John R ^a   Botting, Regina M ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; 6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FLOSULIDE; GCP 28237; IBUPROFEN; INDOMETACIN; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE INHIBITOR; SALICYLATE SODIUM; UNCLASSIFIED DRUG;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; CONFERENCE PAPER; DIGESTIVE SYSTEM PERFORATION; DRUG BINDING SITE; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME INHIBITION; ENZYME SPECIFICITY; GASTROINTESTINAL HEMORRHAGE; HUMAN; INFLAMMATION; NEPHROTOXICITY; OTITIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION;

EID: 0032579940     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00203-9     Document Type: Conference Paper

References (58)

1. Stone E. An account of the success of the bark of the willow in the cure of agues. Phil Trans Roy Soc. 1763;53:195-200.
2. Dreser H. Pharmacologisches über Aspirin (Acetylsalicylsaüre). Pflügers Arch. 1899;76:306-318.
3. Flower RJ. Drugs which inhibit prostaglandin biosynthesis. Pharmacol. Rev. 1974;26:33-67.
4. Whitehouse MW, Haslam JM. Ability of some antirheumatic drugs to uncouple oxidative phosphorylation. Nature 1962; 196:1323-1324.
5. Gould BJ, Smith MJH. Salicylate and aminotransferase. J Pharm Pharmacol. 1965;17:83-88.
6. Gould BJ, Smith MJH. Inhibition of rat brain glutamate decarboxylase activity by salicylate in vitro. J Pharm Pharmacol. 1965;17:15-18.
7. Weiss WP, Campbell PL, Diebler GE, Sokoloff L. Effects of salicylate on amino acid incorporation into protein. J Pharmacol Exp Ther. 1962;136:366-371.
8. Spector WG, Willoughby DA. Anti-inflammatory effects of salicylate in the rat. In: Dixon A StJ, Martin BK, Smith MJH, Wood PHN, eds. Salicylates: An International Symposium. Boston: Little, Brown, 1963:141-147.
9. Collier HOJ. Aspirin. Sci Am. 1963;209:97-108.
10. Collier HOJ. A pharmacological analysis of aspirin. Adv Pharmacol Chemother. 1969;7:333-405.
11. Piper PJ, Vane JR. The release of prostaglandins during anaphylaxis in guinea-pig isolated lungs. In: Mantegazza P, Horton EW, eds. Prostaglandins, Peptides and Amines. London, New York: Academic Press, 1969:15-19.
12. Vane JR. The use of isolated organs for detecting active substances in the circulating blood. Br J Pharmacol Chemother. 1964;23:360-373.
13. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA. 1975;72:2994-2998.
14. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature. 1971;231: 232-235..
15. Smith JH, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nature. 1971;231:235-237.
16. Ferreira SH, Moncada S, Vane JR. Indomethacin and aspirin abolish prostaglandin release from spleen. Nature. 1971; 231:237-239.
17. Hemler M, Lands WEM, Smith WL. Purification of the cyclooxygenase that forms prostaglandins; demonstration of the two forms of iron in the holoenzyme. J Biol Chem. 1976; 251:5575-5579.
18. Smith WL Prostaglandin biosynthesis and its compartmentation in vascular smooth muscle and endothelial cells. Annu Rev Physiol. 1986;48:251-262.
19. 2 synthase-1. Nature. 1994;367:243-249.
20. Roth RJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthetase by aspirin. Proc Natl Acad Sci USA. 1975;72:3073-3067.
21. Luong C, Miller A, Barnett J, et al. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol. 1996;3:927-933.
22. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976;263:663-665.
23. Whittle BJR, Higgs GA, Eakins KE, et al. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature. 1980;284:271-273.
24. Xie W, Robertson DL, Simmons DL. Mitogen-inducible prostaglandin G/H synthase: a new target for nonsteroidal antiinflammatory drugs. Drug Dev Res. 1992;25:249-265.
25. 2 synthase (cyclooxygenase) in human monocytes. J Biol Chem. 1990;265:16737-16740.
26. Masferrer JL, Zweifel BS, Seibert K, Needleman P. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest. 1990;86:1375-1379.
27. Xie W, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA. 1991;88:2692-2696.
28. O'Banion MK, Sadowski HB, Winn V, Young DA. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem. 1991;266: 23261-23267.
29. Kujubu DA, Fletcher BS, Varnum BC, et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem. 1991;266:12866-12872.
30. Sirois J, Richards JS. Purification and characterisation of a novel, distinct isoform of prostaglandin endoperoxide synthase induced by human chorionic gonadotropin in granulosa cells of rat preovulatory follicles. J Biol Chem. 1992; 267:6382-6388.
31. Weissmann G. Prostaglandins as modulators rather than mediators of inflammation. J Lipid Med. 1993;6:275-286.
32. Weissmann G. Aspirin. Sci Am. 1991;264:84-90.
33. Wu KK, Sanduja R, Tsai AL, et al. Aspirin inhibits interleukin-1 induced prostaglandin H synthase expression in cultured endothelial cells. Proc Natl Acad Sci USA. 1991;88: 2384-2387.
34. Clissold SP. Paracetamol and phenacetin. Drugs. 1986; 32(suppl 4):46-59.
35. Flower RJ, Vane JR. Inhibition of prostaglandin synthetase in brain explains the antipyretic activity of paracetamol (4-acetamidophenol). Nature. 1972;240:410-411.
36. Langenbach R, Morham SG, Tiano HF, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell. 1995;83:483-492.
37. Morham SG, Langenbach R, Loftin CD, et al. Prostaglandin synthase 2 gene disruption causes renal pathology in the moust. Cell. 1995;83:473-482.
38. Dinchuck JE, Car BD, Focht RJ, et al. Renal abnormalities and an altered inflammatory response in mice lacking cycloxygenase II. Nature. 1995;378:406-409.
39. Whittle BJR. Neuronal and endothelium-derived mediators in the modulation of the gastric microcirculation: integrity in the balance. Br J Pharmacol. 1993;110:3-17.
40. Rainsford KD, Willis C. Relationship of gastric mucosal damage induced in pigs by antiinflammatory drugs to their effects on prostaglandin production. Dig Dis Sci. 1982;27: 624-635.
41. Chen XS, Sheller JR, Johnson EN, Funk CD. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature. 1994;372:179-182.
42. Mitchell JA, Akarasereenont P, Thiemermann C, et al. Selectivity of non-steroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Sci USA. 1993;90:11693-11697.
43. Meade EA, Smith WL, DeWitt DL Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993;268:6610-6614.
44. Lanza FL. A review of gastric ulcer and gastroduodenal injury in normal volunteers receiving aspirin and other nonsteroidal anti-inflammatory drugs. Scand J Gastroenterol. 1989;24(suppl 163):24-31.
45. Akarasereenont P, Mitchell JA, Thiemermann C, Vane JR. Relative potency of nonsteroid anti-inflammatory drugs as inhibitors of cyclooxygenase-1 or cyclooxygenase-2. Br J Pharmacol. 1994;112(suppl):183P.
46. Garcia Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal anti-inflammatory drugs. Lancet. 1994;343:769-772.
47. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs, Inflamm Res. 1995;44:1-10.
48. Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Nat Acad Sci USA. 1994; 91:12013-12017.
49. Hubbard RC, Mehlisch DR, Jasper DR, et al. SC-58635, a highly selective inhibitor of COX-2, is an effective analgesic in an acute post-surgical pain model. J Invest Med. 1996; 44:293A.
50. Chan C-C, Boyce S, Brideau C, et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharm Exp Ther. 1995;274:1531-1537.
51. Pairet M, Churchill L, Englehardt G. Differential inhibition of COX-1/COX-2 by NSAIDs. In: Bazan N, Botting J, Vane JR, eds. New Targets in Inflammation. Lancaster, London: Kluwer Academic Publishers and William Harvey Press, 1996; 23-38.
52. Churchill L, Graham A, Shih C-K, et al. Selective inhibition of human cyclooxygenase-2 by meloxicam. Inflammopharmacology. 1996;4:125-135.
53. Gans KR, Galbraith W, Roman RJ, et al. Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther. 1990; 254:180-187.
54. Böttcher I, Schweizer A, Glatt M, Werner H. A sulphonamido-indanone CGP 28237 (ZK 34228), a novel nonsteroidal anti-inflammatory agent without gastrointestinal ulcerogenicity in rats. Drugs Exp Clin Res. 1987; 13:237-245.
55. Carr DP, Henn R, Green JR, Böttcher I. Comparison of the systemic inhibition of thromboxane synthesis, anti-inflammatory activity and gastro-intestinal toxicity of non-steroidal anti-inflammatory drugs in the rat. Agents Actions. 1986;19:374-375.
56. Futaki N, Takahashi S, Yokoyama M, et al. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins. 1994;47:55-59.
57. Thun MJ, Namboodiri MM, Heath CWJ. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991 ;325: 1593-1596.
58. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994; 104:1183-1188.